| Literature DB >> 23518664 |
Suzee E Lee1, Maria C Tartaglia, Görsev Yener, Sermin Genç, William W Seeley, Pascual Sanchez-Juan, Fermin Moreno, Mario F Mendez, Eric Klein, Rosa Rademakers, Adolfo López de Munain, Onofre Combarros, Joel H Kramer, Robert O Kenet, Adam L Boxer, Michael D Geschwind, Maria-Luisa Gorno-Tempini, Anna M Karydas, Gil D Rabinovici, Giovanni Coppola, Daniel H Geschwind, Bruce L Miller.
Abstract
Recently, Coppola and colleagues demonstrated that a rare microtubule-associated protein tau (MAPT) sequence variant, c.454G>A (p.A152T) significantly increases the risk of frontotemporal dementia (FTD) spectrum disorders and Alzheimer disease (AD) in a screen of 15,369 subjects. We describe clinical features of 9 patients with neurodegenerative disease (4 women) harboring p.A152T, aged 51 to 79 years at symptom onset. Seven developed FTD spectrum clinical syndromes, including progressive supranuclear palsy syndrome (n=2), behavioral variant FTD (bvFTD, n=1), nonfluent variant primary progressive aphasia (nfvPPA, n=2), and corticobasal syndrome (n=2); 2 patients were diagnosed with clinical AD. Thus, MAPT p.A152T is associated with a variety of FTD spectrum clinical presentations, although patients with clinical AD are also identified. These data warrant larger studies with clinicopathologic correlation to elucidate the influence of this genetic variant on neurodegenerative disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23518664 PMCID: PMC3796183 DOI: 10.1097/WAD.0b013e31828cc357
Source DB: PubMed Journal: Alzheimer Dis Assoc Disord ISSN: 0893-0341 Impact factor: 2.703